Trial Profile
Prospective Observational Study on NovoSeven Room Temperature Stable (VII25) in Patients With Haemophilia A or B
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Eptacog alfa (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms SMART-7
- Sponsors Novo Nordisk
- 11 Jan 2017 New trial record
- 06 Dec 2016 Subanalysis results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology